These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7795272)

  • 21. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.
    van Groeningen CJ; Leyva A; O'Brien AM; Gall HE; Pinedo HM
    Cancer Res; 1986 Sep; 46(9):4831-6. PubMed ID: 2425959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide.
    Rigas JR; Tong WP; Kris MG; Orazem JP; Young CW; Warrell RP
    Cancer Res; 1992 Dec; 52(23):6619-23. PubMed ID: 1423306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
    Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of E7010.
    Yamamoto K; Noda K; Yoshimura A; Fukuoka M; Furuse K; Niitani H
    Cancer Chemother Pharmacol; 1998; 42(2):127-34. PubMed ID: 9654112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
    de Forni M; Bugat R; Chabot GG; Culine S; Extra JM; Gouyette A; Madelaine I; Marty ME; Mathieu-Boué A
    Cancer Res; 1994 Aug; 54(16):4347-54. PubMed ID: 8044782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.
    Panasci L; Stinson SF; Melnychuk D; Sandor V; Miller WH; Batist G; Patenaude F; Bangash N; Panarello L; Alaoui-Jamali M; Sausville E
    J Clin Oncol; 2003 Jan; 21(2):232-40. PubMed ID: 12525514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule.
    Stevenson JP; DeMaria D; Reilly D; Purvis JD; Graham MA; Lockwood G; Drozd M; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1999; 44(3):228-34. PubMed ID: 10453724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
    Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
    Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
    Noe DA; Rowinsky EK; Shen HS; Clarke BV; Grochow LB; McGuire WB; Hantel A; Adams DB; Abeloff MD; Ettinger DS
    Cancer Res; 1990 Aug; 50(15):4595-9. PubMed ID: 2369734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule.
    Adamson PC; Balis FM; Miser J; Wells RJ; Bleyer WA; Williams TE; Gillespie A; Penta JS; Clendeninn NJ; Poplack DG
    Cancer Res; 1990 Aug; 50(15):4464-7. PubMed ID: 2369724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
    Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.